GlassScriptPhysician profile
Charles V Wendling
NPI 1710188867
$1,206.43
in general payments reported to CMS, 2019-2025
19 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $25.17 · 2021: $11.92 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $254.05 | 2019-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $200.73 | 2019 | |
| Genzyme Corporation | $126.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $121.55 | 2019 | |
| Pfizer INC. | $108.18 | 2019-2025 | |
| Gilead Sciences, INC. | $55.72 | 2019-2021 | |
| Exelixis INC. | $44.68 | 2019 | |
| Amgen INC. | $44.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.41 | 2019 | |
| Abbvie INC. | $33.53 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.49 | 2019 | |
| Lilly USA, LLC | $25.37 | 2019 | |
| Array Biopharma INC | $22.70 | 2025 | Braftovi, Tukysa, Mektovi |
| Glaxosmithkline, LLC. | $21.74 | 2025 | Ojjaara, Blenrep |
| Syndax Pharmaceuticals, INC. | $18.92 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wendling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.